Open AccessComparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study
Author(s) -
Hiroyuki Takahashi,
Rika Sakai,
Takayuki Sakuma,
Ayako Matsumura,
Kazuho Miyashita,
Yoshimi Ishii,
Yuki Nakajima,
Ayumi Numata,
Yukako Hattori,
Tatsuya Miyazaki,
Chizuko Hashimoto,
Hideyuki Koharazawa,
Sachiya Takemura,
Jun Taguchi,
Katsumichi Fujimaki,
Hiroyuki Fujita,
Hideaki Nakajima
Publication year - 2020
Publication title -
indian journal of hematology and blood transfusion/indian journal of hematology and blood transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.213
H-Index - 15
eISSN - 0974-0449
pISSN - 0971-4502
DOI - 10.1007/s12288-020-01307-7
Subject(s) - medicine , hematology , lymphoma , retrospective cohort study , stage (stratigraphy) , diffuse large b cell lymphoma , oncology , chemotherapy , paleontology , biology
We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL ( n = 11), limited stage SBL (LSBL; n = 6), and advanced stage SBL (ASBL, n = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group ( P = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, P = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS ( P = 0.01) and PFS ( P = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL.